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C
ancer is a leading cause of death,
with millions of new people diag-
nosed with cancer every year, mak-
ing the development of new methods for 
eﬃcient and speciﬁc delivery of diagnostic 
and therapeutic agents to tumors a perma-
nent challenge. Over the past two decades, the 
introduction of targeted cancer therapeutics in 
the clinic has been a major breakthrough in 
cancer therapy. Currently, targeted delivery 
of diagnosis and/or therapeutic agents to 
tumoral cells uses biological markers selec-
tively expressed or at least overexpressed in 
tumors relative to healthy surrounding and 
distant tissues.1,2
.
In this context, much attention is focused
toward the development of strategies com-
bining molecular targeting and nanoparti-
cle delivery.1,3 Among the wide range of
available nanoparticles, magnetic nanopar-
ticles have emerged as potential biocompa-
tible systems for cancer detection by mag-
netic resonance imaging (MRI) and for
targeted cancer therapy.37 Indeed,magnetic
nanoparticles oﬀer the theoretical potential
to be driven to the tumors by grafting the
nanoparticles with ligands or antibodies
recognizing receptors or antigens overex-
pressed in tumors.1 In vivo, targeted mag-
netic nanoparticles injected intravenously
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ABSTRACT Nanotherapy using targeted magnetic nanoparticles grafted with peptidic ligands
of receptors overexpressed in cancers is a promising therapeutic strategy. However, nanoconjuga-
tion of peptides can dramatically aﬀect their properties with respect to receptor recognition,
mechanism of internalization, intracellular traﬃcking, and fate. Furthermore, investigations are
needed to better understand the mechanism whereby application of an alternating magnetic ﬁeld
to cells containing targeted nanoparticles induces cell death. Here, we designed a nanoplatform
(termed MG-IONP-DY647) composed of an iron oxide nanocrystal decorated with a ligand of a
G-protein coupled receptor, the cholecystokinin-2 receptor (CCK2R) that is overexpressed in several
malignant cancers. MG-IONP-DY647 did not stimulate inﬂammasome of Raw 264.7 macrophages. They recognized cells expressing CCK2R with a high
speciﬁcity, subsequently internalized via a mechanism involving recruitment of β-arrestins, clathrin-coated pits, and dynamin and were directed to
lysosomes. Binding and internalization of MG-IONP-DY647 were dependent on the density of the ligand at the nanoparticle surface and were slowed down
relative to free ligand. Traﬃcking of CCK2R internalized with the nanoparticles was slightly modiﬁed relative to CCK2R internalized in response to free
ligand. Application of an alternating magnetic ﬁeld to cells containing MG-IONP-DY647 induced apoptosis and cell death through a lysosomal death
pathway, demonstrating that cell death is triggered even though nanoparticles of low thermal power are internalized in minute amounts by the cells.
Together with pioneer ﬁndings using iron oxide nanoparticles targeting tumoral cells expressing epidermal growth factor receptor, these data represent a
solid basis for future studies aiming at establishing the proof-of-concept of nanotherapy of cancers using ligand-grafted magnetic nanoparticles speciﬁcally
internalized via cell surface receptors.
KEYWORDS: iron oxide nanoparticles . cholecystokinin-2 receptor . endocrine tumors . internalization . intracellular traﬃcking .
alternating magnetic ﬁeld . lysosomal cell death pathways
accumulate within the tumor, where they can act 
as a thermoablative agent upon application of an 
alternating magnetic ﬁeld. In addition, targeted mag-
netic nanoparticles can serve as nanocarriers of cyto-
toxic agents through the body, enabling their pre-
ferred delivery to primary and metastatic tumors.1
Interestingly, targeted magnetic nanoparticles oﬀer 
the opportunity of combining targeted hyperthermia 
therapy and chemotherapy. Using such therapeutic 
strategies, exposure of tumoral tissues to therapeutic 
agents should be optimized, whereas that of healthy 
tissues should be minimized.
Iron oxide nanoparticles (IONPs), which display low 
toxicity in humans, are the subject of renewed interest 
in the perspective of nanotherapy of cancers.8 A ﬁrst 
ﬁeld of investigation aims at increasing our knowledge 
about engineering targeted iron oxide nanoparticles to 
enhance their ability to eﬃciently reach solid tumors 
after systemic administration. Escape of the nanopar-
ticles from the reticuloendothelial system, their extra-
vascular transport to the tumor, and subsequent tumor 
penetration and accumulation still represent impor-
tant challenges, although key breakthroughs were 
recently made.9,10 Another important point concerns 
the speciﬁcity of targeted nanoparticles, which is often 
far from expected, including in cultured cells in vitro. In  
fact, targeting is usually obtained through the chemical 
grafting of ligands (in the case of receptor targeting) to 
the surface of the nanoparticles. Yet, this nanoconju-
gation can dramatically modify properties of the li-
gands with respect to recognition parameters (kinetics, 
speciﬁcity, aﬃnity), mechanism of internalization, in-
tracellular traﬃcking, and fate.1113 A second ﬁeld of 
active research is related to magnetic hyperthermia 
and mechanisms at the origin of cancer cell death.1315
In vivo studies with transplanted tumors in animals and 
even clinical trials with prostate cancer or brain 
tumor patients have provided the proof-of-concept 
of hyperthermia therapy of cancers with IONPs.16,17
However, in most of the in vivo investigations so 
far reported, high amounts of IONPs were injected 
intravenously or even directly injected into the 
tumors. Therefore, results obtained in these studies 
cannot be generalized to targeted IONPs which 
are actively and speciﬁcally internalized in lower 
amounts by tumoral cells through their cell-surface 
target.
Interestingly, magnetic iron oxide nanoparticles tar-
geting epidermal growth factor (EGF) receptor were 
recently shown to be internalized by tumoral cells and 
to kill the cells upon application of an alternating 
magnetic ﬁeld.13,14,18 Cell death was achieved without 
a perceptible temperature rise and occurred through a 
mechanism involving lysosomal death pathways.13,14,18 
Such data stimulate research aimed at developing strat-
egies of targeted nanotherapy of cancers overexpressing 
other cell surface receptors.
.
The aim of our study was to design and evaluate a
hybrid system (termed MG-IONP-DY647) composed of
an iron oxide nanocrystal decorated with a peptidic
ligand of the cholecystokinin-2 receptor (CCK2R). The
CCK2R was chosen as an example of targeted receptor
because this seven-transmembrane domain peptide
receptor is expressed at high incidence and density in
cancers such as medullary thyroid carcinomas, small
cell lung cancers (SCLC), gastrointestinal stromal tu-
mors (GIST), and insulinomas.1921 Moreover, CCK2R
undergoes rapid internalization and subsequent traf-
ﬁcking to lysosomes following stimulation by its
equally potent natural ligands, gastrin and cholecysto-
kinin (CCK).22,23 Recently, a number of radiolabeled
replicates of CCK or gastrin have been developed, with
the indication of receptor-targeted tumor imaging and
therapy, on the example of imaging probes that are
currently used in the clinic to detect neuroendocrine
tumors overexpressing somatostatin receptors.19,20
However, so far, none of these CCK or gastrin radio-
labels have been approved for clinical use, as their
renal retention and expected radiotoxicity remain a
major drawback.
We demonstrated the ability of MG-IONP-DY647 to
speciﬁcally target cells expressing CCK2R, character-
ized internalization and intracellular traﬃcking of the
nanoparticles, and ﬁnally used them as a targeted
therapeutic agent to induce tumoral cell death through
a cell death lysosomal pathway. Thus, we here conﬁrm
that a small amount of nanoparticles displaying a small
heating power is suﬃcient to induce cell death upon an
alternating magnetic ﬁeld. These data are very promis-
ing in light of the recent concept that lysosomal mem-
brane permeabilization could be an eﬀective way to kill
apoptosis-resistant cancer cells.24
RESULTS
Preparation of Gastrin-Decorated Iron Oxide Magnetic Nano-
particles (MG-IONP-DY647). In order to selectively target
CCK2R withminor cross-recognition of CCK1R, which is
also frequently expressed in tumors,19 gastrin, a selec-
tive CCK2R ligand, was chosen as a cross-linked pep-
tide to IONPs. Previous data showing that radiolabeled
gastrin injected into animals is abundantly retained
by the kidney due to the presence of five glutamic
acids in the middle of the peptidic sequence were
taken into account for the design of the gastrin
replicate (Figure 1a).25,26 Thus, a synthetic replicate of
gastrin, termed MG, which contains the pharma-
cophore of natural gastrin but has its Glu-Glu-Glu-
Glu-Glu sequence replaced by Cys-Lys-Ser-Ser-Glu
was synthesized. Importantly, this peptide shares its
C-terminal bioactive sequencewith the natural agonist
CCK, which is used as reference peptide for CCK2R
internalization studies (Figure 1a). Control experiments
established that MG bound to CCK2Rwith only 7.3-fold
lower affinity than CCK and stimulated production of
inositol phosphates through phospholipase-C activa-
tion with the same efficacy as CCK and only 1.3-fold 
lower potency (Supporting Information, Figure 1a,b). 
Finally, MG triggered CCK2R internalization as de-
monstrated by endocytosis of GFP-tagged CCK2R 
and trapping of MG-DY647 within endocytosic vesicles 
(Supporting Information, Figure 1c).
The strategy illustrated in Figure 1b was used to 
obtain magnetic nanoparticles decorated with both 
gastrin replicate (MG) and ﬂuorescent label (DY647). 
These were termed MG-IONP-DY647. Batches of 
MG-IONP-DY647 decorated with 24, 100, or 240 molecules 
of MG per nanoparticle were routinely prepared.
Starting nanoparticles were commercial iron oxide 
nanoparticles having characteristics shown in Support-
ing Information Table 1. Heating properties of these 
nanoparticles were measured in a magnetic ﬁeld of 
frequency 275 kHz, with an amplitude ranging from 
24 to 40 mT (Figure 2a). At the largest applied magnetic
ﬁeld, the speciﬁc absorption rate was 13 W/g. The size
of MG-IONP-DY647 determined by transmission elec-
tron microscopy was 8.7 ( 1.6 nm (Figure 2c), and
analysis by dynamic light scattering in a biological
medium enriched with 0.5% fetal calf serum showed
a distribution around a size of 40 nm, with a signiﬁcant
amount of objects reaching 100 nm size. Size distribu-
tion was not signiﬁcantly aﬀected by the density of MG
grafted at the nanoparticle surface (Figure 2b). Hence,
in the biological medium MG-IONP-DY647 behaved
either as clusters of several individual nanoparticles
and/or as likely bound serum proteins.
Absence of Effect of MG-IONP-DY647 Nanoparticles on Macro-
phage Inflammasome. To evaluate biocompatibility of
MG-IONP-DY647, we determined whether the nano-
particles could activate macrophages. Indeed, side-
targets of nanoparticles in vivo are resident macro-
phages of liver and spleen as well as monocytes and
circulating macrophages involved in the inflammation
Figure 1. Schematic representation of nanoconjugation method to obtain magnetic iron oxide nanoparticles. (a) Primary
structure of gastrin (G17), synthetic replicate of gastrin (MG), and cholecystokinin (CCK) used in the study. Amino acids in red
are common to CCK and gastrin (two natural ligands of CCK2R) and correspond to the biologically active region of the two
regulatory peptides. (b) Scheme for the conjugation reaction ofMG tomagnetic iron nanoparticles yieldingMG-IONP-DY647.
Details of the protocols are given in the Materials and Methods section. The layer colored in yellow represents coating by
polyethylene glycol 2000.
CCK2R-293, previously used to precisely delineate
agonist-induced CCK2R internalization.22
Confocal microscopy images show slow binding of
MG-IONP-DY647 to themembrane of Flp-In CCK2R-293
cells, which were progressively illuminated at their sur-
face upon contact with MG-IONP-DY647 (Figure 4a).
This binding of MG-IONP-DY647 to the cell surface was
slower that previously appreciated with unconjugated
ligands.22 Following binding, MG-IONP-DY647 abun-
dantly internalized over the time (Figure 4a). Only
minor nonspeciﬁc binding/uptake of red ﬂuorescence
was seen on HEK293 cells lacking CCK2R (Figure 4c) or
on Flp-In CCK2R-293 cells incubated in the presence of
a saturating concentration (1 μM) of CCK (Figure 4b).
Subcellular localization of MG-IONP-DY647 was as-
sessed by transmission electron microscopy. As illu-
strated in Figure 4d, MG-IONP-DY647 were located in
endocytosic vesicles. The number of nanoparticles in
small vesicles, as well as the number of vesicles con-
taining nanoparticles, increased within the ﬁrst 23 h
of incubation. Then, the size of vesicles containing
MG-IONP-DY647 clearly increased, showing intracellu-
lar accumulation and storage of highly concentrated
nanoparticles (Figure 4d).
Given that nanoparticles can enter cells through
several ways, the initial mechanism of MG-IONP-DY647
internalization was investigated. We previously showed
that themolecularmechanismof agonist-induced inter-
nalization of CCK2R involves recruitment of nonvisual
arrestins, clathrin-coatedpits, anddynamin.22 In Figure 5a,
confocal microscopy imaging of cells transiently
expressing GFP-tagged β-arrestin2 incubated with
MG-IONP-DY647 shows ﬂuorescent nanoparticles in
intracellular vesicles containing β-arrestin2. Further-
more, internalization of MG-IONP-DY647 was blocked
in the presence of chlorpromazine, a clathrin inhibitor,
at 75 μM (Figure 5c; doseresponse eﬀect shown
in the Supporting Information, Figure 2). In line with
this result, incubation of MG-IONP-DY647 with cells
transiently expressing eYFP-tagged clathrin polypep-
tide showed abundant intracellular co-localization
(Figure 5d). Furthermore, MG-IONP-DY647 internaliza-
tion was inhibited in the presence of the dynamin
inhibitor dynasore (Figure 5e). The possibility of uptake
through caveoles was also examined by testing the
eﬀect of ﬁlipin, an inhibitor of caveoles. However,
abundant internalization of MG-IONP-DY647 in the
presence of ﬁlipin was still observed, supporting that
MG-IONP-DY647 endocytosis did not signiﬁcantly occur
through caveoles in Flp-In CCK2R-293 cells (Figure 5f).
Intracellular traﬃcking of internalized MG-IONP-
DY647 was then investigated. First, co-localization of
MG-IONP-DY647 with CCK2R during intracellular traf-
ﬁcking was studied and quantiﬁed in cells expressing
GFP-tagged CCK2R. As shown in Figure 6a and b, inter-
nalized MG-IONP-DY647, as well as CCK-DY647, co-
localized with CCK2R in endocytosic vesicles. However,
Figure 2. Physicochemical properties of MG-IONP-DY647.
(a) Speciﬁc absorption rate of a mother solution of magnetic 
nanoparticles measured at a frequency of 275 kHz as a 
function of the magnetic ﬁeld amplitude. Solution concen-
tration was 5.9 mg Fe/mL. (b) Dynamic light scattering 
analysis of MG-IONP-DY647 in solution (0.1 mg Fe/mL) in 
RPMI 1640 medium containing 0.5% FBS. The iron nano-
particle suspension was sonicated for 10 min on ice before 
analysis. (c) Transmission electron microscopy analysis of 
MG-IONP-DY647 showing size homogeneity of IONP nana-
particles. An average size of 8.7 ( 1.6 nm was calculated.
processes.4,27,28 Incubation of MG-IONP-DY647 in vitro 
with Raw 264.7 mouse leukemic monocyte macro-
phages or with mouse peritoneal macrophages re-
sulted in rapid and abundant uptake of nanoparticles 
(Figure 3a,b). Then, activation of macrophages was 
tested on both untreated and LPS-stimulated Raw 
264.7 cells by measuring the secretion of the cytokine 
IL-1β (Figure 3c). We found that in contrast to nanosi-
lica nanoparticles recognized as potent inducers of 
inflammasome and which elicit release of the cytokine
IL-1β,29 MG-IONP-DY647 at concentrations up to 2 mg/mL 
did not trigger significant release of IL-1β from both 
untreated and LPS-primed Raw 264.7 cells (Figure 3c). 
These first results are in favor of biocompatibility of 
MG-IONP-DY647.
Specific Targeting of HEK293 Cells Expressing CCK2R by MG-
IONP-DY647 and Intracellular Trafficking of the Nanoparticles. 
Our targeting strategy using MG-IONP-DY647 requires 
specific recognition of nanoconjugated MG molecules 
by the CCK2R expressed at the cell surface and inter-
nalization of the nanoparticles through the endocyto-
sic machinery usually involved in CCK2R endocytosis. 
Yet, nanoconjugated MG molecules might modify its 
pharmacological properties. We therefore character-
ized binding and internalization of MG-IONP-DY647 
in HEK293 cells expressing CCK2R, namely, Flp-In
the time-courses of co-localization diﬀered. Indeed, 
comparing Figure 6a and b shows that co-localization 
between CCK-DY647 and CCK2R was persistent, 
whereas progressive and partial dissociation between 
MG-IONP-DY647 and GFP-tagged CCK2R was noted at 
earlier times. These results suggest that nanoconjuga-
tion of MG to magnetic nanoparticles aﬀects the 
traﬃcking properties of internalized CCK2R and per-
haps enables the CCK2R to recycle faster than when 
stimulated with unconjugated ligand. To examine this 
possibility, we evaluated co-localization of CCK2R stim-
ulated with MG-IONP-DY647 versus CCK-DY647 in 
vesicles expressing Rab11, a small GTPase of recycling 
vesicles.30 As represented in Figure 7a, localization of 
CCK2R-GFP in Rab11-DsRed containing vesicles was 
maximal after 4 h of incubation with MG-IONP-DY647 
and then slightly decreased. When stimulated with 
CCK-DY647 (or with MG-DY647, not shown), the loca-
lization proﬁle of CCK2R in DsRed-tagged Rab-11 
positive vesicles was signiﬁcantly diﬀerent, with a 
slower increase to a maximum after 5 h of incubation.
Thus, CCK2R stimulated with MG-IONP-DY647 seems
to recycle faster than when stimulated with the non-
conjugated ligands; however, the recycling takes sev-
eral hours, as previously demonstrated.22
Last, the intracellular fate of MG-IONP-DY647 was
analyzed using the lysosome staining reagent Lyso-
Traker and by incubating MG-IONP-DY647 with cells
transiently expressing DsRed-tagged Rab7, a small
GTPase of late endosomes and lysosomes. As illus-
trated in Figure 7b, a high proportion of LysoTracker-
stained lysosomes contained MG-IONP-DY647 after
times longer than 1 h of incubation, and co-localization
images between MG-IONP-DY647 and Rab7-Ds-Red
were observed in most cells (Figure 7c).
Together, this set of results demonstrates that
nanoconjugation of MG to IONPs enables active endocy-
tosis of the nanoparticles, and, by facilitating separation of
the receptor from endocytosic vesicles, nanoconjugation
slightly accelerates the presence of the targeted receptor
in slowly recycling vesicles. Importantly, MG-IONP-DY647
uptake by cells remains fully dependent on CCK2R
Figure 3. Absence of inﬂammasome activation of macrophages by MG-IONP-DY647. (a) Uptake of nanoparticles by Raw
264.7 mouse leukemic monocyte macrophages. Confocal microscopy images illustrating Raw 264.7 cells incubated with
MG-IONP-DY647 (8 μg Fe/mL) for indicated times at 37 C. (b) Uptake of nanoparticles by mouse peritoneal macrophages.
Resident peritoneal cells were harvested by washing the peritoneal cavity of female Swiss mice with sterile NaCl 0.9%. Two
hours after seeding,macrophageswere incubatedwithMG-IONP-DY647 (8 μg Fe/mL) for indicated times at 37 C. (c) Assay of
IL-1β secretion. Untreated or LPS-primed Raw 264.7 cells were stimulated with increasing concentrations of MG-IONP-DY647
or with nanosilica (0.2 mg/mL) for 6 h at 37 C. IL-1β release in culture supernatant was assayed with an ELISA kit. Results are
mean ( SEM of three separate experiments.
internalization and involves recruitment of β-arrestin2, 
clathrin-coated pits, and dynamin. Furthermore, interna-
lized MG-IONP-DY647 are directed to lysosomes, where 
they are trapped for times up to 24 h.
Targeting of InR1G9-CCK2R Tumoral Endocrine Cells by MG-
IONP-DY647 Nanoparticles. Tumoral cells display profound 
modifications relative to “normal” cells, which affect 
the plasma membrane, intracellular trafficking as well 
as lysosomal volume, composition, and cellular distri-
bution.31 Therefore, we next characterized the behav-
ior of MG-IONP-DY647 toward tumoral cells expressing 
or not CCK2R. Specificity and kinetics of MG-IONP-
DY647 binding, accumulation in lysosomes, and de-
pendency on the density of MG at the nanoparticle sur-
face were precisely investigated on the tumoral endocrine 
cell line expressing CCK2R, namely, InR1G9-CCK2R.32
Confocal microscopy observations conﬁrmed spe-
ciﬁc binding of MG-IONP-DY647 to the tumoral cells 
and subsequent internalization, as no signiﬁcant up-
take was detected in InR1G9 lacking CCK2R or 
InR1G9-CCK2R incubated in the presence of 1 μM
CCK (Supporting Information, Figure 3a,b,c). MG-
IONP-DY647 binding and internalization determined
by FACS indicates that the amount of MG-IONP-DY647
taken up by the cells increased with the time of
incubation but much slower than that of CCK-DY647,
which was maximum between 1 and 3 h of incubation
and then decreased (Figure 8). Furthermore, the
amount of bound and internalized MG-IONP-DY647
by the cells increased proportionally to MG density at
the surface of the nanoparticles. After 24 h of incuba-
tion, magnetic measurements showed an amount of
2.2 ( 0.2 pg of iron per cell incubated with nano-
particles grafted with 100 molecules of MG (termed
100MG-IONP-DY647 in Figures 8 and 9). FACS quanti-
ﬁcations also conﬁrmed high speciﬁcity of targeting
since nanoparticles without grafted MG (termed IONP-
DY647 in Figure 8) were taken up in very low amounts
by InR1G9-CCK2R tumoral cells and MG-IONP-DY647
were poorly taken up by InR1G9 tumoral cells lacking
CCK2R at their surface (9.1 ( 2.1% of nonspeciﬁc
binding after 24 h of incubation, not shown). Finally,
Figure 4. MG-IONP-DY647 speciﬁcally bind to Flp-In CCK2R-293 cells and are subsequently internalized and trapped within
the cells. (a, b, c) Confocalmicroscopy images illustrating speciﬁcity of uptake ofMG-IONP-DY647. (a) HEK293 cells expressing
CCK2R (Flp-In CCK2R-293) were incubated at 37 CwithMG-IONP-DY647 alone (8 μg Fe/ml) or (b) in the presence of 1 μMCCK.
(c) HEK293 lacking CCK2R were incubated with MG-IONP-DY647. (d) Electron microscopy analysis of MG-IONP-DY647
internalization in Flp-In CCK2R-293 cells. Cells were incubated with nanoparticles (8 μg Fe/mL) for indicated times at 37 C.
Arrows depict the presence of nanoparticles in endocytosic vesicles.
lysosome occupancy by MG-IONP-DY647 (illustrated in 
the Supporting Information, Figure 3d) was quantiﬁed 
by confocal microscopy. Kinetics of accumulation of 
MG-IONP-DY647 in lysosomes were in agreement with 
that of binding/internalization (Figure 9). After 24 h 
of incubation, lysosome occupancy by nanoparticles 
grafted with 24, 100, or 240 MG molecules reached 
31.6 ( 1.9%, 46.8 ( 0.7%, or 49.8 ( 1.8%, respectively. 
No signiﬁcant presence of nanoparticles without MG 
(termed IONP-DY647) could be noticed in lysosomes 
after 24 h of incubation (Figure 9). On the other hand, 
lysosome occupancy by unconjugated CCK-DY647 was 
maximal at 1 and 3 h of incubation and then drama-
tically decreased to almost disappear at 24 h, suggest-
ing ligand degradation in lysosomes.
Internalized MG-IONP-DY647 by Tumoral Cells Induce Apop-
tosis and Cause Cell Death upon an Alternating Magnetic Field. 
Having assessed the ability of MG-IONP-DY647 to 
specifically target endocrine tumoral cells expressing 
CCK2R and to abundantly accumulate in lysosomes of 
these cells, the next step was to test the ability of the 
nanoparticles to induce cell death upon exposure to an 
alternating magnetic field. For this purpose, InR1G9-
CCK2R tumoral cells incubated with MG-IONP-DY647 
for 24 h were maintained at 37 C and exposed to an 
alternating magnetic field (275 kHz, 40 or 52 mT for 
2 h). Controls were composed of cells having inter-
nalized ligand without nanoparticles (CCK-DY647) and 
cells having internalized MG-IONP-DY647 but that 
were not exposed to the alternating magnetic field. 
In preliminary experiments, we also checked that cells 
incubated with nanoparticles without grafted gastrin 
and that did not internalize these nanoparticles (Figure 9)
behaved similarly to cells having internalized CCK-DY647
(not illustrated).
The impact of magnetic ﬁeld treatment was deter-
mined by counting cells labeled by FITC-tagged an-
nexin V and/or propidium iodure, which identiﬁed
early apoptotic, late apoptotic, and necrotic cells,
respectively. As shown in Figure 10, application of
the alternating magnetic ﬁeld during 2 h caused the
cells to enter into apoptosis. The total number of
apoptotic cells reached 17.1 ( 1.6% at 40 mT ampli-
tude and 36.4 ( 5.5% at 52 mT amplitude. In control
cells having internalized unconjugated CCK-DY647
and exposed to the same magnetic ﬁeld amplitudes,
apoptotic cells represented 3.0( 0.7% and11.2( 0.4%
of the total cell population. The number of necrotic
cells, namely, cells that became positive for propidium
iodure labelingonly,was not signiﬁcantwith amagnetic
ﬁeld of 40mT, whereas it increased up to 5.9% at 52mT.
Determination of cell survival 24 h after magnetic ﬁeld
exposure using theMTT assay indicated that amagnetic
ﬁeldof 40or 52mTkilled 26.9( 7.6%and67.1( 9.9%of
tumoral cells, respectively. It is worthy to note that a
magnetic ﬁeld of 52mTaﬀected the viability of cells that
had not accumulated nanoparticles, whereas an ampli-
tude of 40 mT had a minor eﬀect (Figure 10a,b).
Since a recent study with EGF-grafted nanoparticles
documented that an alternatingmagnetic ﬁeld caused
lysosomemembrane permeabilization, we determined
whether it was also the case with MG-IONP-DY647
nanoparticles. First, the eﬀect of a magnetic ﬁeld was
evaluated on lysosome staining with LysoTracker Red.
As evidenced in Figure 10c, exposure of cells contain-
ing MG-IONP-DY647 to a magnetic ﬁeld of 40 or 52 mT
Figure 5. Internalization of MG-IONP-DY647 in Flp-In CCK2R-293 cells occurs through CCK2R endocytosic machinery. (a) MG-
IONP-DY647 internalize through recruitment of β-arrestin2. Flp-In CCK2R-293 cells transiently expressing β-arrestin-2-GFP
were incubated with MG-IONP-DY647. At initial time, β-arrestin-2 (in green) was uniformely scattered in the cytoplasm,
whereas after 30minof stimulationwithnanoparticles, it was also seen in endocytosic vesicles togetherwithMG-IONP-DY647
(in yellow). (b, c, d) MG-IONP-DY647 internalize via clathrin-coated pits. Flp-In CCK2R-293 cells were incubated at 37 C for
60 min (b) with MG-IONP-DY467 alone or (c) in the presence of the clathrin-coated-pits inhibitor chlorpromazine (75 μM).
Doseresponse eﬀect of chlorpromazine is shown in Supporting Information Figure 2. (d) Flp-In CCK2R-293 cells transiently
expressing clathrin-LCa-eYFP were incubated with MG-IONP-DY647 at 37 C. Co-localization between MG-IONP-DY647 and
clathrin-LCa-eYFP is seen in yellow. (e) MG-IONP-DY647 internalization requires dynamin. Flp-InCCK2R-293 cells were
incubated with MG-IONP-DY467 in the presence of dynasor (160 μM). Dynasor eﬃciently inhibited internalization. (f)
MG-IONP-DY647 internalization is not sensitive to ﬁlipin, an inhibitor of caveoles. Flp-In CCK2R-293 cells were incubatedwith
MG-IONP-DY467 in the presence of ﬁlipin (10 μM). No signiﬁcant inhibition of internalization could be observed.
induced drops of lysosome stain, suggesting leaking 
of lysosome content (see Supporting Information, 
Figure 4 for an illustration). Furthermore, the eﬀect of 
the magnetic ﬁeld on apoptosis was almost totally 
reversed by E64d, an inhibitor of cysteine proteases 
such as lysosomal cathepsins B, L, C, H, and P (Figure 10a).  
Pepstatin A, an inhibitor of aspartyl peptidases such as 
lysosomal cathepsin D, did not reverse cell death (not 
shown). The eﬀect of the magnetic ﬁeld on apoptosis 
was also signiﬁcantly diminished by chloroquine, a 
weak base aﬀecting activity of lysosomes and autop-
hagy (at 40 mT, amount of apoptotic cells: 6.8 ( 0.5% in 
the presence of chloroquine versus 17.1 ( 1.6% in the 
absence of chloroquine, not illustrated).
This set of results shows that application of an 
alternating magnetic ﬁeld to InR1G9 tumoral cells 
containing low amounts of MG-IONP-DY647 nanopar-
ticles internalized speciﬁcally through cell surface 
CCK2R causes apoptosis and cell death through a 
mechanism involving lysosome leaking and lysosomal 
cysteine proteases.
DISCUSSION
In the context of increasing success of targeted
therapy of cancers and accumulation of data showing
overexpression of peptide receptors in several types of
tumors as well as their contributing role in cancer
development,33,34 a synthetic analogue of gastrin was
conjugated to ironoxidenanoparticles inorder toproduce
a magnetic nanoplatform for targeted therapy of tumors
overexpressing CCK2R. The synthetic analogue of gastrin
(MG) pharmacologically behaved similarly to CCK, the
most eﬃcient and potent natural agonist of CCK2R.35
We ﬁrst showed thatMG-IONP-DY647 nanoparticles,
even at high concentrations, do not promote inﬂam-
mation, as evidenced by the absence of IL-1β secretion
by cultured macrophages. This result conﬁrms the
recognized good biocompatibility of iron oxide nano-
particles. Binding, uptake, and intracellular traﬃcking
of MG-IONP-DY647 nanoparticles and the underlying
cellular and molecular mechanisms were character-
ized on HEK293 cells, a reference cell model for char-
acterization of membrane receptor internalization,
Figure 6. MG-IONP-DY647 dissociate faster from internalized CCK2R than unconjugated ﬂuorescent ligand. Confocal
microscopy images illustrating changes in co-localization between MG-IONP-DY647 and CCK2R-GFP over time. HEK293 cells
transiently expressing CCK2R-GFP were incubated with (a) MG-IONP-DY647 (8 μg Fe/ml) or (b) CCK-DY647 (50 nM). Merged
images show that CCK2R-GFP does not co-localize with MG-IONP-DY647 as long as CCK-DY647 does.
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as well as on tumoral cell lines (InR1G9) expressing or
not CCK2R.32 We found that MG-IONP-DY647 nano-
particles binding and internalization were entirely
dependent on the presence of CCK2R at the cell sur-
face. Nevertheless, kinetics of binding and internaliza-
tion of MG-IONP-DY647 weremuch slower than that of
ﬂuorescent unconjugated CCK (CCK-DY647), although
MG-IONP-DY647 nanoparticles internalized together
with CCK2R through the initial molecular mechanism
described for CCK- or gastrin-induced internalization
of CCK2R.22 Indeed, key steps in the internalizationprocess
such as β-arrestin2 recruitment and involvement of
clathrin-coated pits and of dynamin were observed with
both MG-IONP-DY647 (this study) and CCK-DY647.22
Analysis of CCK2R intracellular traﬃcking in HEK293
cells expressingeitherGFP-taggedCCK2RorDsRed-tagged
Figure 7. MG-IONP-DY647 accelerate slow recycling of internalized CCK2R and accumulate in lysosomes. (a) MG-IONP-DY647
modulate CCK2R recycling. HEK293 cells transiently coexpressing CCK2R-GFP and Rab11-dsRed were incubated with MG-IONP-
DY647nanoparticles (8μgFe/mL) orCCK-DY647 (50nM).Cells expressingbothCCK2R-GFPandRab11-dsRedwerecounted, and the
percentage of cells presenting co-localization between the CCK2R-GFP and Rab11-dsRed was determined. Results are the mean
( SEM of three distinct experiments with degree of conﬁdence *0.01 < p < 0.05. In the inset, an example of confocal microscopy
images of co-localization between CCK2R-GFP and Rab-11-DsRed is shown. (b, c) Internalized nanoconjugatedMG-IONP-DY647 are
directed to lysosomes. (b) Flp-In CCK2R-293 cells were preincubated with 75 μM LysoTracker (green) for 30 min before incubation
with MG-IONP-DY647. (c) Flp-In CCK2R-293 cells transiently expressing Rab7-DsRed (green) were incubated with MG-IONP-DY647.
Figure 8. Time-course and speciﬁcity of uptake of MG-
IONP-DY647 by tumoral endocrine cells InR1G9-CCK2R.
InR1G9-CCK2R cells were incubated with MG-IONP-DY647
(16 μg Fe/mL) or CCK-DY647 (0.1 μM) for indicated times at
37 C. Kinetics are shown for nanoparticles without grafted
MG (labeled as IONP-DY647) as well as for nanoparticles
grafted with 24, 100, and 240 MG molecules per nanopar-
ticle. Fluorescence was measured by ﬂow cytometry, and
results are expressed as % of maximum ﬂuorescence asso-
ciated with the cells and are the mean ( SEM of three
separate experiments.
Figure 9. MG-IONP-DY647 traﬃcking to lysosomes of InR1G9
tumoral endocrine cells. InR1G9-CCK2R cells were incubated
at 37 C with MG-IONP-DY647 (16 μg Fe/mL), IONP-DY647
(16 μg Fe/mL), or CCK-DY647 (0.1 μM). LysoTracker (75 nM)
was added 30 min before analysis on a confocal microscope.
The presence of nanoparticles in lysosomeswas quantiﬁed on
the basis of co-localization between DY-647 and LysoTracker
ﬂuorescences using ImageJ softaware and Jacop Plugin. On
average 23000 cells/experiment were analyzed. Results are
the mean ( SEM of three separate experiments.
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Rab11, a small GTPase of slowly recycling vesicles,
strongly supports that nanoconjugation of MG aﬀected
both the stability of the endocytosic complexes and
CCK2R traﬃcking. Indeed, after stimulation with MG-
IONP-DY647, CCK2R was found in vesicles distinct from
that containing the nanoparticles and was targeted to
recycling vesicles containing Rab11 earlier than CCK2R
stimulated with unconjugated CCK or gastrin (Figures 6
and 7). These results are consistent with data showing
that internalization and traﬃcking of a G-protein-
coupled receptor are initially dictated by its ligand.36,37
Our data are in agreement with a report showing
that nanoconjugation of an antibody directed against
EGF receptor modulates antibody-induced internaliza-
tion of this receptor.12 Furthermore, it has been also
shown that ligand dissociation from G-protein-coupled
receptors (GPCRs) and subsequent degradation by
endosomal peptidases control traﬃcking and endoso-
mal signaling of peptide receptors. For example, endothe-
lin-converting enzyme 1 (ECE-1) rapidly degrades
substance P, calcitonin gene-related peptide (CGRP),
and somatostatin peptide in endosomes, disrupting
the peptide-receptor-β-arrestin complex and then al-
lowing β-arrestins to return to the cytoplasm and
receptors, to recycle.3840 For class B GPCRs such as
CCK2R, dissociation from β-arrestin in endosomes is
necessary for recycling and resensitization.37 As an alter-
native hypothesis to explain the increased time-course of
CCK2R localization in slowly recycling vesicles, CCK2R
internalization as oligomers due to simultaneous binding
of MG-IONP-DY647 to several receptor molecules at a
time must be also considered. Such multiligand binding
was described for neuropeptide Y1 receptor when tar-
geted by neuropeptide Y-decorated quantum dots.11
Figure 10. Internalized MG-IONP-DY647 by tumoral cells exposed to an alternating magnetic ﬁeld induce apoptosis and
cause cell death by aﬀecting lysosome integrity. InR1G9-CCK2R cells were incubated with MG-IONP-DY647 (16 μg Fe/mL)
or CCK-DY647 (0.1 μM) for 24 h at 37 C.When indicated, E64d (10 μM)was added in themedium. Cells were then exposed for
2 h to an alternatingmagnetic ﬁeld (275 kHz, 40 or 52mT) at 37 C. (a) Apoptotic and necrotic cells were counted 4 h after the
end ofmagnetic ﬁeld exposure by confocalmicroscopy analysis of cells labeledwith FITC-annexin V and/or propidum iodure.
Cells labeled only with FITC-annexin V were regarded as early apoptotic cells, those doubled-labeled with FITC-annexin/
propidium iodure were regarded as late apoptotic cells, and those labeled only with propidium iodure were necrotic cells. (b)
Cell survival was determined using MTT assay 24 h after the end of magnetic ﬁeld exposure. (c) Lysosome staining with
LysoTracker Redwas determined 30min after the end ofmagnetic ﬁeld exposure. Results are themean( SEMof three to ﬁve
separate experiments. *0.01 < p < 0.05; **0.001 < p < 0.01; ***p < 0.001.
Importantly, besides modiﬁcations of CCK2R traﬃcking,
internalized MG-IONP-DY647 nanoparticles are directed
to lysosomes, where they accumulate both in HEK293
and InR1G9 tumoral cells. Of interest, internalized
MG-IONP-DY647 were much more stable in lysosomes
than unconjugated ﬂuorescent CCK, which became al-
most nondetectable after 24 h of contact with the cells.
Last, we started to explore the opportunity oﬀered
by magnetic nanoparticles accumulated into lyso-
somes of tumoral cells to act as a therapeutic agent
inducing cell death upon exposure to an alternating
magnetic ﬁeld. The results that were obtained clearly
demonstrate that exposure of tumoral cells containing
actively internalized MG-IONP-DY647 to an alternating
magnetic ﬁeld of moderate strength causes apoptosis
followed by cell death. Moreover, ﬁrst data on the
mechanisms at the origin of cell death support the
involvement of lysosomes and cysteine proteases, since
staining of lysosomes with pH-independent LysoTracker
Red was diminished by exposure of cells containing
targeted nanoparticles to a magnetic ﬁeld. Moreover,
E64d inhibitor was able to reverse the eﬀect of the
magnetic ﬁeld on apoptosis. On this basis, and according
to our current knowledge, lysosomemembranepermea-
bilization followed by leaking of cathepsin B is likely at
the origin of tumoral cell death. Thus, MG-IONP-DY647
exposed to an alternating magnetic ﬁeld behaved as a
lysosomotropic agent in tumoral endocrine cells. Several
other agents have been shown to induce lysosome
membrane permeabilization and subsequent activation
of lysosomal death pathways.24 EGF-grafted iron nano-
particles internalized by tumoral cells and exposed to an
alternating magnetic ﬁeld were previously reported to
cause lysosomal membrane permeabilization, together
with production of reactive oxygen species (ROS) and
subsequent cell death.13 It is worthy to note that ROS
formation, lysosomal membrane permeabilization, and
cell death occurred in the absence of any perceptible
temperature rise in the incubation medium of the cells
(refs 13, 14, and 18 and this study). These experimental
data, as well as basic calculations,41,42 support the view
that minute amounts of nanoparticles located in lyso-
somes are unable to elicit temperature rise, including
inside the cells. Alternatively, local temperature
increase,15,43 nanoparticle rotation,13 or nanoparticle
high-frequency motion44 has been proposed.
Whatever the initial mechanism at the origin of
lysosomal membrane permeabilization, data from the
current study highlight the feasibility of cell death
induction with very small quantities of actively and
speciﬁcally internalized nanoparticles. Basic calculation
using the model presented in ref 45 indicates that
inducing a temperature increase of 5 C in a 3 mm size
tumor with MG-IONP-DY647 would require approxi-
mately 165 pg Fe/cell, which is a completely unrealistic
objective using targeted nanoparticles which are inter-
nalized only via cell surface receptors. Here, a maximum
of 2.2 pg Fe/cell could be speciﬁcally internalized via cell
surface CCK2R receptors. Although this low amount of
nanoparticles was suﬃcient to induce cell death, it likely
explains, together with the low heating power of the
iron oxide nanoparticles, the relatively modest level of
cell death achieved in this study using a magnetic ﬁeld
of 40mT.Our results showthat increasing the amplitude
of the magnetic ﬁeld from 40 mT to 52 mT augmented
the death rate of cells containing nanoparticles. How-
ever, such a treatment also caused damage to cells that
had not accumulated nanoparticles. Therefore, optimi-
zation of the nanoparticles will be required in order to
enhance their killing eﬃciency. Their size and composi-
tion could be changed to increase their heating power.
CONCLUSIONS
Grafting of gastrin to iron oxide nanoparticles en-
abled highly speciﬁc targeting of HEK293 and tumoral
endocrine cells INR1G9 expressing CCK2R, a G-protein-
coupled receptor overexpressed in endocrine tumors.
Subsequently, nanoparticles undergo internalization
with CCK2R through a mechanism involving β-arrestins,
clathrin-coated pits, and dynamin composing the endo-
cytosic machinery of CCK2R. Internalized nanoparticles
are thendirected to lysosomes,where they accumulate in
minute amount (2.2 pg Fe/cell). Application of an alter-
natingmagneticﬁeld to cells containingMG-IONP-DY647
induced apoptosis and cell death through a lysosomal
death pathway, demonstrating that cell death is trig-
gered even though nanoparticles of low thermal power
are internalized in minute amounts by the cells. These
data are verypromising in light of the recent concept that
lysosomal membrane permeabilization could be an ef-
fective way to kill apoptosis-resistant cancer cells.24
Together with previous pioneer ﬁndings,13,14 they repre-
sent a solid basis for future studies aimed at establishing
the proof-of-concept of nanotherapy of cancers using
ligand-grafted magnetic nanoparticles speciﬁcally inter-
nalized via their cell surface receptors.
MATERIALS AND METHODS
Chemical and Biological Materials. Iron oxide nanoparticles were 
purchased from Genovis (Lund, Sweden). The characteristics of 
these IONP provided by the manufacturer are given in Support-
ing Information Table 1. A stable replicate of CCK, sulfated 
[Thr28,Nle31]-CCK 25-33, was kindly given by Prof. L. Moroder46
.
and is referred to as CCK. 125I-Sodium (2000 Ci/mmol) and [myo-
3H]inositol (5 μCi/mL) were from Perkin-Elmer Life Sciences.
CCK was conjugated with Bolton-Hunter reagent, purified, and
radioiodinated as described previously47 and is referred to as
125I-CCK. Gastrin replicate termed MG (Figure 1) was synthe-
sized by Covalab (Villeurbanne, France). DY647-tagged CCK and
MG were obtained according to the procedure described for
glucose insulinotropic polypeptide by coupling the peptides to 
NHS-DY647-PEG1 (Dyomics GmbH, Jena, Germany)48 and are 
referred to as CCK-DY647 and MG-DY647, respectively. The 
following products were supplied as follows: 3-maleimidopro-
pionic acid N-hydroxysuccinimide ester (Thermo Scientific), 
magnetic columns (Miltenyi, Berisch, Gladback, Germany), spe-
cific inhibitor of dynamin, dynasore (Calbiochem), an inhibitor 
of clathrin-dependent uptake, chlorpromazine (Sigma-Aldrich), 
an inhibitor of caveoles, filipin (Sigma), and LysoTracker 
(Invitrogen).
The cDNA encoding CCK2R was subcloned in pcDNA3 
vector, and green ﬂuorescent protein (GFP)-tagged CCK2R 
was generated by subcloning the CCK2R cDNA in pEGFP-N1 
(BD Biosciences Clontech). DsRed-tagged Rab11, DsRed-tagged 
Rab7, and clathrin-LCa-eYFP were obtained from Addgene 
(www.addgene.org). GFP-tagged β-arrestin2 was kindly sup-
plied by Robert Lefkowitz (Duke University Medical Center, 
Durham, NC, USA). The annexin V binding apoptosis assay kit 
was from AAT Bioquest, Inc. (Sunnyvale, CA, USA). Cell lines were 
HEK 293 cells stably expressing CCK2R (Flp-In CCK2R-293) 
obtained using the Flp-In system (HEK293) (Invitrogen) as 
previously described;22 the glucagon-producing hamster tu-
moral cell line InR1G9 stably expressing CCK2R obtained as 
previously described (InR1G9-CCK2R),32 and the Raw 264.7 
mouse leukemic monocyte macrophage cell line. Lab-Tek II 
chambers were from Thermo Fisher (Rochester, NY, USA), and 
glass-bottom Cellview dishes were from Greiner Bio-one, Cour-
taboeuf, France.
Preparation of Gastrin-Decorated Magnetic Nanoparticles (MG-IONP-
DY647). The protocol used for grafting 100 molecules of MG per 
IONP was as follows: an aliquot of IONP (80 μL of IONP at a 
concentration of 12 mg Fe3O4/mL) was added to 120 μL of  
sodium phosphate buffer (0.2 M Na2HPO4 pH 7.3, 150 mM NaCl) 
and sonicated for 10 min on melting ice (Bioblock Scientific 
88154). NHS-DY647-PEG1 (12 μg) in solution in dimethyl form-
amide (24 μL) was added and allowed to react for 2 h at room 
temperature. Then, 53 μg of 3-maleimidopropionic acid 
N-hydroxysuccinimide ester in solution in 10 μL of DMF was 
added and incubated at room temperature for 1 h. MG (100 μL 
of a solution of 30% DMF, 70% H2O containing 20 μg of peptide) 
was added to IONP and allowed to react for 2 h. Finally, free 
maleimide functions were saturated by addition of an excess of 
cystein (62 μg in 50 μL of reaction buffer). Grafted nanoparticles 
were recovered through a magnet column in H2O. MG-IONP-
DY647 were stored at 4 C. Before use, MG-IONP-DY647 were 
always sonicated on ice for 10 min. The amount of recovered 
nanoparticles was determined by magnetic measurement 
(see below), and the density of grafted MG at the nanoparticle 
surface was assessed by measuring the ability of different 
dilutions of MG-IONP-DY647 to stimulate production of ino-
sitol phosphates in Flp-In CCK2R-293 cells. The density of MG 
was calculated from a doseresponse curve with free MG 
(Supplementary Figure 1b).
Dynamic Light Scattering Measurements of Hydrodynamic Diameter. 
A suspension of iron nanoparticles at 0.1 mg/mL was prepared 
in RPMI 1640 medium containing 0.5% FBS. The iron nanopar-
ticle suspension was sonicated for 10 min on ice. After tem-
perature equilibrium to 20 C, the particle size was measured by 
dynamic light scattering using Nanotrac 250 (Microtrac, York, 
PA, USA).
Specific Absorption Rate Measurements. A 300 μL solution of 
IONPs at 5.9 mg Fe/mL was used for specific absorption rate 
measurements. The temperature increase of the sample placed 
in a 275 kHz alternating magnetic field delivered by a commer-
cial magnetic inductor (Fives Celes, Lautenback, France) during 
100 s was measured. A blank sample containing water was used 
in parallel in order to remove the contribution of eddy current 
to the temperature increase. Temperature measurements 
were performed using a thermal probe (Reflex, Neoptix, Canada). 
The specific absorption rate was calculated using standard 
formula and taking into account the specific heat of water.
Determination of Iron Concentrations and Amounts. Amounts of 
iron were determined by magnetic measurements using a 
vibrating sample magnetometer (PPMS, Quantum Design, USA). 
First, we checked the value of concentration and saturation
.
magnetization provided by the manufacturer by performing
magnetic measurements on a dried powder of MG-IONP-
DY647. Hysteresis cycles at 270 K were measured, and the linear
slope corresponding to the diamagnetic signal was removed
from the raw measurement. The remaining signal was fitted
with a distribution of Langevin functions in parallel with a fit of
the NP size distribution obtained by TEM. The magnetization
and concentration values determined from this fit are 73 ( 10
Am2/kg Fe3O4 and 2.1 ( 0.2 mg/mL, respectively, when
80 Am2/kg Fe3O4 and 2 mg/mL were expected from manufac-
turer data. We thus considered manufacturer data as reliable
and used them in the following. To determine iron content in
cells, a suspension containing a known number of dried cells
((2.5 ( 0.2)  106) was put into a magnetic measurement
capsule, the excess of liquid removed, and the remaining liquid
allowed to evaporate. Hysteresis loops were measured at 300 K
at a magnetic field of 5 T. The obtained magnetization was
divided by the saturation magnetization of the nanoparticles
provided by the nanoparticle supplier (107 Am2/kg Fe) and the
number of cells to obtain the iron content per cell.
Transmission Electron Microscopy. Flp-In CCK2R-293 or HEK293
cells were grown in poly-L-lysine-coated wells and incubated
with MG-IONP-DY647 (8 μg Fe/mL) for indicated times in
phosphate-buffered saline (PBS) 0.2% BSA. After two washes,
cells were fixed with 4% glutaraldehyde in Sorensen buffer for
4 h at 4 C. After washes, cells were postfixed in 1% osmium
tetraoxide (osmium 2%, saccharose 0.25M, Sorensen 0.05M) for
1 h at 20 C, followed by washings with distilled water and
uranyl acetate 2% for 12 h at 4 C. After dehydratation, 70 nm
sections of cells embedded in EMBed 812 resin were stained
with uranyl acetate and lead citrate and examined with a TEM
(Hitachi HU12A, Japan) operating at 75 kV.
Cell Culture and Transfections. Flp-In CCK2R-293 and HEK293
cells were cultured in Dulbecco's modified Eagle's medium
(DMEM) containing 10% FBS and 1% penicillinstreptomycin
(Invitrogen). InR1G9 and Raw cells were cultured in RPMI 1640
medium containing 10% fetal bovine serum (FBS) and 1%
penicillinstreptomycin (Invitrogen). Cells were grown in a
humidified atmosphere at 95% air and 5% CO2. Transfections
of HEK293 cells were carried out using polyethyleneimine
(Polyscience) on 10 cm dishes containing 2.0 106 cells, which
were seeded 24 h before transfection. Plasmids containing
cDNA encoding GFP-tagged CCK2R, β-arrestin2-GFP, Rab7-
DsRed, Rab11-DsRed, or clathrin-LCa-eYFP were transfected.
Analysis of Macrophage Inflammasome Activation. To evaluate
IL-1β secretion, Raw 264.7 macrophages were primed with
ultrapure lipopolysaccharide (LPS, 500 ng/mL) (Invivogen,
Toulouse, France), for 4 h. This step of LPS stimulation triggers
synthesis and intracellular accumulation of pro-IL-1β.49 Medium
was removed and cells were washed twice with PBS. Then, Raw
264.7 cells were stimulated with IONP-MG-DY647 or silica
nanoparticles for 6 h at 37 C. This second step of stimulation
is expected to assemble a multiprotein complex termed an
inflammasome, leading to enzymatic cleavage of pro-IL1β by
caspase-1 and release of its active form, IL1β.49 Supernatants
were recovered and assayed for IL-1β secretionwith an ELISA kit
according to the manufacturer's instructions.
Receptor Binding and Inositol Phosphate Assays. Cells were plated
onto 24-well plates and grown for 24 h. Binding assays were
performed on attached cells using 125I-CCK according to the
protocol previously described in detail.50 IC50 values were
calculated from homologous 125I-CCK competition binding
experiments using the nonlinear curve-fitting software Graph-
Pad Prism (San Diego, CA, USA). Inositol phosphate production
was determined as previously described after 24 h of incubation
in DMEM containing 2 μCi/mL of myo-[2-3H]inositol (specific
activity: 1025 Ci/mmol).50
Quantification of MG-IONP-DY647 Binding and Uptake by Flow Cyto-
metry. Cells were seeded onto poly-L-lysine-coated 12-well plates
at a density of 150 103 cells/well and grown for 24 h on RPMI
1640 medium containing 2% FBS. MG-IONP-DY647 (4 to 8 μg of
Fe) or CCK-DY647 (0.1 μM) in 250 μL ofmediumwere added and
incubated at 37 C in a 5% CO2 atmosphere for the desired
times. Then, cells were rinsed twicewith ice-cold PBS containing
0.5% BSA and once with PBS alone. Cells were recovered and
transferred to FACS tubes. Cell-associated fluorescence was 
determined using a BD FACSCalibur flow cytometer. In parallel, 
samples of cells were collected for magnetic determination 
of iron.
Internalization and Trafficking Studies. Internalization and traf-
ficking of nanoparticles were characterized using a Zeiss laser 
scanning microscope (LSM-510). Routinely, cells that had been 
eventually transfected 24 h earlier were plated ((∼80100)  
103 cells/compartment) onto poly-L-lysine-coated four-com-
partment Cellview or Lab-Tek chambered coverglass. After 
overnight growth, cells were rinsed with PBS and incubated 
with MG-IONP-DY647 (4 to 16 μg Fe/mL) or CCK-DY647 (0.1 or 
0.01 μM) in 250 μL of PBS containing 0.5% BSA (for HEK cells) or 
RPMI 1640 medium containing 10% FBS and 1% penicillin 
streptomycin (for INR1G9 cells) completed or not with inhibi-
tors. For lysosome staining, cells were incubated for 30 min in 
the presence of 75 nM LysoTracker Red DND-99 prior to 
stimulation with nanoparticles or CCK-DY647. Collected images 
were analyzed using ImageJ softaware and the Jacop plugin, 
which provided cytofluorograms and Pearson's and overlap 
coefficients that account for co-localization.
Cell Treatment by an Alternating Magnetic Field. Cells were seeded 
24 h before the experiments onto four-compartment Cell-
view dishes at a density of ∼80  103 cells/compartment in 
RPMI 1640 medium containing 10% FBS and 1% penicillin 
streptomycin. Cells were rinsed with PBS and incubated with 
MG-IONP-DY647 (16 μg Fe/mL) or DY647 (0.1 μM) for 24 h at 
37 C in RPMI 1640 buffered with 10 mM Hepes buffer pH 7.4 
and containing 0.5% FBS and 1% penicillinstreptomycin 
with or without protease inhibitors E64d (10 μM), peptatin A 
(100 μM), or chloroquine (25 μM). Incubation medium was 
withdrawn, and cells were rinsed twice with incubation medi-
um. Attached cells were exposed to an alternating magnetic 
field (275 kHz, 40 or 52 mT) delivered by a commercial magnetic 
inductor (Fives Celes, Lautenback, France) for 2 h. The magnetic 
field amplitude was measured by a homemade pick-up coil. The 
latter was calibrated by measuring the high-frequency mag-
netic field on an electromagnet in which the current/magnetic 
field relationship was calibrated in dc and the ac current could 
be accurately measured using a noncontact ac current probe 
(Tektronix, P6021).51 The inner diameter of the coil was 3.5 cm 
so that the Cellview dish fit in its middle. The magnetic field was 
applied in the plane of the Cellview dish. The temperature of the 
Cellview dish was controlled using a thermal probe (Reflex, 
Neoptix, Canada) placed in the incubation medium of the cells. 
The temperature of the Cellview dish was maintained at 37.0 ( 
0.4 C thanks to an air gun placed below it. Control samples 
were also maintained out of the cell incubator during hy-
perthermia experiments, and their temperature was regulated 
similarly to the assay samples. At the end of the experiments, 
cells were placed in a humidified atmosphere at 5% CO2 at 
37 C for 4 h.
Determination of Apoptosis and Cell Death. The effects of mag-
netic field treatment were investigated as follows: first, 
apoptotic and necrotic cells labeled with FITC-annexinV 
and/or propidum idodure (Cell Meter Annexin V apoptosis 
832 assay kit, AAT Bioquest) were counted 4 h after the 
end of magnetic field exposure. Counting of labeled cells 
was carried out by analyzing confocal microscopy images 
representing populations of 23000 cells/experiment using 
ImageJ software. Lysosome integrity was determined using 
LysoTracker Red staining reagent, which was added (at 75 nM) 
to cells at the beginning of the magnetic field runs. Quanti-
fication of staining was performed 30 min later by analyz-
ing 23000 cells/experiment using Morpho Expert software 
(Explora Nova, La Rochelle, France). Cell death was determined 
24 h post-magnetic field treatment using a MTT viability assay 
(MTT: [(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide], Sigma-Aldrich).
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